Company profile
Redbiotec company profile
Redbiotec is a private biotech company in Zurich-Schlieren. Founded in 2006 as a spin-off of ETH Zürich, the company has won several awards and is backed by experienced institutional and private investors. During its era as a vaccine innovator, Redbiotec has sold its CMV vaccine business to Pfizer in 2015 and also created an HSV-2 immunotherapy. Presently, Redbiotec is dedicated to developing bacteria-based gene therapies to treat cancer and genetic disorders. The proprietary bacteria platform accommodates large and diverse therapeutic cargos and is designed to overcome many delivery hurdles faced by other vehicles.
Business identity
- Website
- http://www.redbiotec.ch
- Contact email
- [email protected]
- Phone number
- +41 44 200 23 20
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 11-50 employees
- Revenue range
- $0+
- Founded
- 2006-11-11
Headquarters
- Headquarters
- Schlieren, Zurich, Switzerland
- Postal code
- 8952
- Country code
- CH
- Continent
- Europe